Key result
GLP-1 receptor agonists (exenatide and liraglutide) are effective for treating PCOS, particularly in women who are overweight, glucose intolerant, or have cardiovascular disease risk factors.
Why the study?
GLP-1 receptor agonists offer an opportunity to simultaneously address comorbid conditions and phenotypic presentations of PCOS, prompting an update on trials conducted during the last 5 years.
Do GLP-1 receptor agonists improve outcomes in women with polycystic ovary syndrome?
Do GLP-1 receptor agonists improve outcomes in women with polycystic ovary syndrome?
GLP-1 receptor agonists like exenatide and liraglutide offer a promising therapeutic option for women with PCOS, particularly those with metabolic or cardiovascular risk factors.
May support GLP-1 RA consideration in select PCOS patients; leaves open need for RCTs to confirm outcomes.
Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) offer a unique opportunity to simultaneously address various comorbid associated conditions and phenotypic presentations of polycystic ovary syndrome (PCOS) as these agents improve insulin sensitivity, reduce cardiovascular disease (CVD) risk, result in weight loss, and improve nonalcoholic fatty liver disease.Areas covered: The authors describe trials conducted during the last 5 years and provide an update on exenatide and liraglutide use in PCOS women. Information from the studies investigating GLP-1 RAs effects on reducing CVD risk in PCOS is also presented.Expert opinion: Exenatide and liraglutide are good options for the treatment of PCOS when used alone or in combination with metformin. Especially strong consideration should be given to GLP-1 RAs when developing treatment strategies for PCOS women who are overweight or obese, glucose intolerant, have CVD or its attendant risk factors, and/or are seeking treatment for infertility.
No takes yet. Share an insight, caveat, or question.
Siamashvili et al. (2021) conducted a review in Polycystic ovary syndrome (PCOS). GLP-1 receptor agonists (exenatide and liraglutide) was evaluated. GLP-1 receptor agonists (exenatide and liraglutide) are effective for treating PCOS, particularly in women who are overweight, glucose intolerant, or have cardiovascular disease risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: